According to Peter Smith, Ph.D., senior VP, nonclinical development sciences at Millennium Pharmaceuticals: The Takeda Oncology Company, shortages in funding, manpower, and patient availability have created the proverbial perfect storm in the current clinical trial system. “The fact that traditional clinical trial endpoints in assessing novel agents are being reconsidered only puts more pressure on an already strained system," he says. Jerome Bailey, VP, early phase business center, at Omnicare Clinical Research, says the number of inclusion/exclusion criteria has almost doubled in an effort to recruit… Experts on this topic Peter Smith, Ph.D., Senior VP, Nonclinical Development Sciences at Millennium Pharmaceuticals: The Takeda Oncology Company Jerome Bailey, VP, Early Phase Business Center, at Omnicare Clinical Research Jamie Dananberg, M.D., Executive Director of Clinical Pharmacology at Eli Lilly and Company Brian Sanderson, M.D., Medical Director, Chiltern Early Phase Alan Copa, Pharm.D., President of Clinical Operations for Cetero Research
